Drug intelligence / Profile preview

TST013

Development stage: Preclinical
Lead developer: Transcenta
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TST013 is an antibody-drug conjugate (ADC) candidate developed by Transcenta. It targets a validated tumor antigen, though the specific antigen has not been publicly disclosed as of mid-2025. Preclinical data indicate that TST013 demonstrates significantly improved anti-tumor activity compared to benchmark ADCs and exhibits an improved tolerability profile, supporting its further development in oncology. The drug is currently in preclinical development and has not yet entered clinical trials[1][8].

Beyond the preview

Go deeper on TST013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TST013.

Explore the full profile